CBER’s New Director “Marks” A New Era For Biologics Regulation
This article was originally published in RPM Report
Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.
You may also be interested in...
The US agency seeks candidates for the executive position in charge of its research policy apparatus.
Agency seeks candidates for the executive position in charge of its research policy apparatus.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.